Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial of Pembrolizumab (MK-3475) and Trametinib Focused on Advanced KRAS Mutant Non-small Cell Lung Cancer

NCT03299088 is registered in ClinicalTrials.gov with Jonathan Riess as lead sponsor.

NCT NCT03299088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03299088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial of Pembrolizumab (MK-3475) and Trametinib Focused on Advanced KRAS Mutant Non-small Cell Lung Cancer
Lead sponsor
Jonathan Riess
Phase
Phase 1
Overall status
Completed
Start date
June 26, 2018
Completion date
June 25, 2024
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kras gene mutation, metastatic non-squamous non-small cell lung carcinoma, recurrent non-squamous non-small cell lung carcinoma, stage iv non-small cell lung cancer ajcc v7